Biocom Partnering Conference: Pharma, VCs Hungry For Deals, But Good Assets Hard To Find
Executive Summary
Pharma business development executives, venture capital investors and small life science companies came together at Biocom's Global Life Science Partnering Conference in San Diego to talk about deal-making and financing.
You may also be interested in...
INTERVIEW: Celgene's head dealmaker strikes a fair balance
Celgene is known among biotechnology firms for being a disciplined buyer and an ideal collaborator – a reputation in which the company's head dealmaker George Golumbeski takes a lot of pride.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.